Antonio Mariscal Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonio Mariscal Martínez has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Iciar Pascual Miguel
Department of General and Digestive Surgery, Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain
3 shared publications E. Iglesias Bravo
Servicio de Ginecología, Hospital Virgen de Valme, Sevilla, Spain
2 shared publicationsH. Peris Alvà
Unidad de Diagnóstico por la Imagen de la Mama, Servicio de Radiología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
2 shared publications- Joan Francesc Julián
Department of General and Digestive Surgery, Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain
2 shared publications M. Luna Tomás
Servicio de Ginecología y Obstetricia, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
2 shared publicationsP. Puyalto de Pablo
Servicio de Radiología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
2 shared publications
Latest Publications
- 19 September 2024
- Published by Elsevier in Radiología (English Edition)
- Vol. 66 (5) , 419-430
Contrast-enhanced mammography and preoperative magnetic seed placement in breast cancer patients for the detection of residual disease following neoadjuvant systemic therapy
- 19 September 2024
- Published by Elsevier in Radiología (English Edition)
- Vol. 66 (5) , 419-430
Contrast-enhanced mammography and preoperative magnetic seed placement in breast cancer patients for the detection of residual disease following neoadjuvant systemic therapy
- 30 May 2024
- Published by Elsevier in Radiologia
- Vol. 66 (5) , 419-430
Mamografía con contraste y marcaje con semilla magnética para la detección de enfermedad residual en el cáncer de mama tras tratamiento neoadyuvante
- 30 May 2024
- Published by Elsevier in Radiologia
- Vol. 66 (5) , 419-430
Mamografía con contraste y marcaje con semilla magnética para la detección de enfermedad residual en el cáncer de mama tras tratamiento neoadyuvante
- Open Access
Unravelling the Encapsulation of DNA and Other Biomolecules in HAp Microcalcifications of Human Breast Cancer Tissues by Raman Imaging
Microcalcifications are detected through mammography screening and, depending on their morphology and distribution (BI-RADS classification), they can be considered one of the first indicators of suspicious cancer lesions. However, the formation of hydroxyapatite (HAp) calcifications and their relationship with malignancy remains unknown. In this work, we report the most detailed three-dimensional biochemical analysis of breast cancer microcalcifications to date, combining 3D Raman spectroscopy imaging and advanced multivariate analysis in order to investigate in depth the molecular composition of HAp calcifications found in 26 breast cancer tissue biopsies. We demonstrate that DNA has been naturally adsorbed and encapsulated inside HAp microcalcifications. Furthermore, we also show the encapsulation of other relevant biomolecules in HAp calcifications, such as lipids, proteins, cytochrome C and polysaccharides. The demonstration of natural DNA biomineralization, particularly in the tumor microenvironment, represents an unprecedented advance in the field, as it can pave the way to understanding the role of HAp in malignant tissues.
Open AccessUnravelling the Encapsulation of DNA and Other Biomolecules in HAp Microcalcifications of Human Breast Cancer Tissues by Raman Imaging
Microcalcifications are detected through mammography screening and, depending on their morphology and distribution (BI-RADS classification), they can be considered one of the first indicators of suspicious cancer lesions. However, the formation of hydroxyapatite (HAp) calcifications and their relationship with malignancy remains unknown. In this work, we report the most detailed three-dimensional biochemical analysis of breast cancer microcalcifications to date, combining 3D Raman spectroscopy imaging and advanced multivariate analysis in order to investigate in depth the molecular composition of HAp calcifications found in 26 breast cancer tissue biopsies. We demonstrate that DNA has been naturally adsorbed and encapsulated inside HAp microcalcifications. Furthermore, we also show the encapsulation of other relevant biomolecules in HAp calcifications, such as lipids, proteins, cytochrome C and polysaccharides. The demonstration of natural DNA biomineralization, particularly in the tumor microenvironment, represents an unprecedented advance in the field, as it can pave the way to understanding the role of HAp in malignant tissues.
- Open Access
- 3 January 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 6
Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences between paclitaxel and other drugs.
- 3 January 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 6
Open AccessNanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences between paclitaxel and other drugs.
- Open Access
- 16 June 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 252
Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
The aim of this study was to investigate the incidence and prognostic value of disseminated tumor cells in bone marrow of breast carcinoma patients with early disease, and to analyze this finding in relation to lymph node involvement, determined by sentinel lymph node (SLN) biopsy analysis, and to prognostic factors of interest. 104 patients with operable (T<3 cm) breast cancer and clinically- and sonographically-negative axillary lymph nodes were scheduled for SLN biopsy. Bone marrow aspirates were collected before the start of surgery from both iliac crests, and mononuclear cell layers were separated by density centrifugation (Lymphoprep). Slide preparations were then examined for the presence of disseminated tumor cells by immunocytochemistry with anti-cytokeratin antibodies (A45-B/B3). Lymphoscintigraphy was performed 2 hours after intratumor administration of 2 mCi (74 MBq) of 99mTc colloidal albumin. The SLN was evaluated for the presence of tumor cells by hematoxylin-eosin staining and, when negative, by immunocytochemistry using anti-cytokeratin antibody (CAM 5.2). Survival analyses and comparative analyses were performed on the results of bone marrow determinations, SLN biopsy, and known prognostic factors, including breast cancer subtypes according to the simplified classification based on ER, PR and HER2. Lymph node and hematogenous dissemination occur in one-third of patients with early-stage breast cancer, although not necessarily simultaneously. In our study, disseminated tumor cells were identified in 22% of bone marrow aspirates, whereas 28% of patients had axillary lymph node involvement. Simultaneous lymph node and bone marrow involvement was found in only 5 patients (nonsignificant). In the survival study (60 months), a higher, although nonsignificant rate of disease-related events (13%) was seen in patients with disseminated tumor cells in bone marrow, and a significant association of events was documented with the known, more aggressive tumor subtypes: triple negative receptor status (21%) and positive ERBB2 status (29%). Tumor cell detection in bone marrow can be considered a valid prognostic parameter in patients with early disease. However, the classic prognostic factors remain highly relevant, and the newer breast cancer subtypes are also useful for this purpose.
- 16 June 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 252
Open AccessPrognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
The aim of this study was to investigate the incidence and prognostic value of disseminated tumor cells in bone marrow of breast carcinoma patients with early disease, and to analyze this finding in relation to lymph node involvement, determined by sentinel lymph node (SLN) biopsy analysis, and to prognostic factors of interest. 104 patients with operable (T<3 cm) breast cancer and clinically- and sonographically-negative axillary lymph nodes were scheduled for SLN biopsy. Bone marrow aspirates were collected before the start of surgery from both iliac crests, and mononuclear cell layers were separated by density centrifugation (Lymphoprep). Slide preparations were then examined for the presence of disseminated tumor cells by immunocytochemistry with anti-cytokeratin antibodies (A45-B/B3). Lymphoscintigraphy was performed 2 hours after intratumor administration of 2 mCi (74 MBq) of 99mTc colloidal albumin. The SLN was evaluated for the presence of tumor cells by hematoxylin-eosin staining and, when negative, by immunocytochemistry using anti-cytokeratin antibody (CAM 5.2). Survival analyses and comparative analyses were performed on the results of bone marrow determinations, SLN biopsy, and known prognostic factors, including breast cancer subtypes according to the simplified classification based on ER, PR and HER2. Lymph node and hematogenous dissemination occur in one-third of patients with early-stage breast cancer, although not necessarily simultaneously. In our study, disseminated tumor cells were identified in 22% of bone marrow aspirates, whereas 28% of patients had axillary lymph node involvement. Simultaneous lymph node and bone marrow involvement was found in only 5 patients (nonsignificant). In the survival study (60 months), a higher, although nonsignificant rate of disease-related events (13%) was seen in patients with disseminated tumor cells in bone marrow, and a significant association of events was documented with the known, more aggressive tumor subtypes: triple negative receptor status (21%) and positive ERBB2 status (29%). Tumor cell detection in bone marrow can be considered a valid prognostic parameter in patients with early disease. However, the classic prognostic factors remain highly relevant, and the newer breast cancer subtypes are also useful for this purpose.